Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments
- PMID: 26318558
- DOI: 10.1016/j.tube.2015.08.001
Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments
Abstract
Dormant, slow-growing, antibiotic-tolerant Mycobacterium tuberculosis undermine the shortening of tuberculosis treatment to less than 6 months and are thought to be characterised by intracellular lipid bodies. Antibiotic effects on such persisting bacilli escape evaluation as they cannot be readily cultured. We identified cells containing lipid bodies in sputum smears from 86 newly diagnosed pulmonary tuberculosis patients and monitored these cells daily in 42 patients over the first 14 days of treatment with rifampicin, the experimental compound SQ-109, or both agents combined. Counts of Nile-Red-positive lipid-body containing cells were correlated with those of Auramine-O-positive cells and colony forming units of viable Mycobacterium tuberculosis on agar plates. Rifampicin but not SQ-109 significantly reduced colony forming units but all treatments distinctively and significantly changed the proportions of lipid body-containing bacilli and viable Mycobacterium tuberculosis. Monitoring lipid-body containing bacilli in sputum during treatment with experimental antituberculosis regimens may identify putative treatment-shortening regimens.
Keywords: Dormancy; Fluorescence microscopy; Mycobacterium tuberculosis; Rifampicin.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis.S Afr Med J. 1996 Feb;86(2):155-8. S Afr Med J. 1996. PMID: 8619142
-
The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis.Tuber Lung Dis. 1992 Feb;73(1):33-8. doi: 10.1016/0962-8479(92)90077-W. Tuber Lung Dis. 1992. PMID: 1326348 Clinical Trial.
-
Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis.Clin Infect Dis. 2015 Jul 1;61(1):1-8. doi: 10.1093/cid/civ195. Epub 2015 Mar 16. Clin Infect Dis. 2015. PMID: 25778753 Free PMC article.
-
The early bactericidal activity of anti-tuberculosis drugs: a literature review.Tuberculosis (Edinb). 2008 Aug;88 Suppl 1:S75-83. doi: 10.1016/S1472-9792(08)70038-6. Tuberculosis (Edinb). 2008. PMID: 18762155 Review.
-
Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease.Soc Appl Bacteriol Symp Ser. 1996;25:72S-80S. Soc Appl Bacteriol Symp Ser. 1996. PMID: 8972122 Review. No abstract available.
Cited by
-
Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.BMC Med. 2016 Feb 4;14:19. doi: 10.1186/s12916-016-0565-y. BMC Med. 2016. PMID: 26847437 Free PMC article. Clinical Trial.
-
Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits.Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0002421. doi: 10.1128/AAC.00024-21. Epub 2021 Aug 17. Antimicrob Agents Chemother. 2021. PMID: 34228540 Free PMC article.
-
Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture.Antimicrob Agents Chemother. 2019 Sep 23;63(10):e00652-19. doi: 10.1128/AAC.00652-19. Print 2019 Oct. Antimicrob Agents Chemother. 2019. PMID: 31358585 Free PMC article.
-
Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management.Front Cell Infect Microbiol. 2022 Sep 23;12:943545. doi: 10.3389/fcimb.2022.943545. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36211964 Free PMC article. Review.
-
Systematic assessment of clinical and bacteriological markers for tuberculosis reveals discordance and inaccuracy of symptom-based diagnosis for treatment response monitoring.Front Med (Lausanne). 2022 Oct 28;9:992451. doi: 10.3389/fmed.2022.992451. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36419786 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources